search

Active clinical trials for "Carcinoma, Renal Cell"

Results 441-450 of 1644

Advantage of a Fast-recovery Protocol for Minimally Invasive Kidney Surgery

Renal Cell Carcinoma

Shorten the time spent in the hospital (hospitalization duration) by optimizing the pre, per and postoperative care is of major medical and economic importance. Minimally invasive surgery allows a faster recovery than open surgery. However, we need to ensure an early and secure return to normality in order to discharge patients safely from the hospital. Clinical and biological parameters need to be controlled post-surgery. This work is going to evaluate the efficacity of a fast - recovery program with incoming patients receiving minimally invasive surgery (laparoscopic or robotic) of partial and total nephrectomy. The implementation of a medical and surgical fast-recovery program could Lower the average duration of stay in hospital (at least by 1 day) with no increase of morbidity Insure the absence of complications after 6 months home

Recruiting14 enrollment criteria

Biomarkers of Renal Cancer

Renal Cell CarcinomaTumor3 more

The aim of the present study is the identification, in liquid biopsies, of a new molecular panel able to discriminate renal cancer patients from controls, to discriminate patients with a malignant lesion from those with a benign mass, to determine aggressiveness of RCC, and to differentiate the most common histological subtypes of RCC (clear cell, papillary 1, papillary 2, and chromophobe). This new molecular panel will be combined with clinical parameters to provide a screening test and to improve the accuracy and specificity of diagnosis, prognosis, and histological classification of renal cancer.

Recruiting17 enrollment criteria

At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious,...

All Diagnosed Health ConditionsADD/ADHD59 more

We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research. We make it easy for patients to contribute to research for medical conditions that matter most to them, regardless of their location or ability to travel.

Recruiting6 enrollment criteria

Kidney Cancer DNA Registry

Renal Cancer

This registry will help us develop better methods of: Preventing these cancers Diagnosing these cancers Treating these cancers

Recruiting14 enrollment criteria

Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug...

Renal Cell CarcinomaLung Carcinoma1 more

This study will examine blood, bone marrow, tumor and tissue samples from patients with cancer to study tumor resistance to chemotherapy (drug treatment). Many patients with cancer improve initially with chemotherapy, but then have a disease relapse, after which their tumor no longer responds to treatment. Other patients tumors are drug-resistant from the start. The study will look for "resistance factors"-substances in blood and tissues that render tumors resistant to chemotherapy. The findings may provide information needed to develop methods of combating drug resistance. Patients with cancer who are 18 years or older may be eligible for this study. Participants will have 40 milliliters (3 tablespoons) of blood drawn at the beginning of the study; additional samples will be obtained periodically during the course of treatment. A small sample of tumor or normal tissue will be taken from patients who undergo surgery or tumor biopsy (removal of a small piece of tumor) for medical reasons or as part of a research treatment protocol. Patients who do not require surgery or biopsy may be asked permission to obtain a tumor sample. Depending on the location of the tumor, this may be done by: 1) withdrawing bone marrow through a small needle; 2) removing fluid from the chest or abdomen; 3) removing a small tumor sample through a needle; or 4) removing the sample with a small incision into or around the tumor. These procedures will be done only if they are of low risk to the patient.

Recruiting10 enrollment criteria

Patient Reported Outcomes by Patients With Metastatic Renal Cell Carcinoma

Metastatic Renal Cell CarcinomaKidney Cancer4 more

The purpose of PRORECECA is to test whether adding weekly active patient-reported outcomes to the treatment of patients with metastatic renal cell carcinoma can improve patient-reported physical function.

Not yet recruiting12 enrollment criteria

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population

Immune Checkpoint InhibitorsMetastatic Solid Tumor5 more

The aim of this study is to describe the outcomes in American Indian patients receiving immunotherapy in a multi-institution retrospective study at several other high-volume centers that care for this patient population and to identify any healthcare disparities that can lead to future interventional studies.

Active6 enrollment criteria

Safety Study of MGD009 in B7-H3-expressing Tumors

MesotheliomaBladder Cancer11 more

The purpose of this study is to evaluate the safety of MGD009 when given to patients with B7-H3-expressing tumors. The study will also evaluate what is the highest dose of MGD009 that can be given safely. Assessments will be done to see how the drug acts in the body (pharmacokinetics (PK), pharmacodynamics (PD) and to evaluate potential anti-tumor activity of MGD009.

Terminated23 enrollment criteria

Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)

Advanced CancerPancreatic Cancer5 more

Determine Phase 2 dose of study drug

Terminated27 enrollment criteria

PRednisone Plus EVerolimus in Patients With Metastatic Renal Cell Cancer After Failure of VEGFR...

Metastatic Renal Cancer

This is a multicenter prospective study that includes all patients with metastatic Renal Cell Cancer (RCC) pre- treated with VEGFR TKI in eight Italian cancer centers. Everolimus is formulated as tablets of 5-10 mg strength, blister-packed under aluminium foil in units of 10 tablets. Prednisone will be dispensed to patients at the dose of 5 mg twice daily (BID). Everolimus at dose of 10 mg (one 10 mg tablet or two 5 mg tablets). Both drugs will be self-administered orally, continuously from Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death or discontinuation for any other reason. A treatment cycle consists of 28 days.

Terminated24 enrollment criteria
1...444546...165

Need Help? Contact our team!


We'll reach out to this number within 24 hrs